Characteristic | Total (N = 20) | Bexarotene (n = 16) | Placebo (n = 4) |
---|---|---|---|
Age at screening, yr | 75.5 ± 6.8 | 74.9 ± 6.6 | 78.1 ± 8.0 |
Male sex | 7 (35.0) | 6 (37.5) | 1 (25.0) |
White race | 19 (95.0) | 15 (93.8) | 4 (100.0) |
Years of education | 14.2 ± 4.7 | 14.7 ± 4.9 | 12.3 ± 3.3 |
Years of cognitive symptoms | 4.3 ± 1.9 | 4.6 ± 1.9 | 2.8 ± 0.96 |
MMSE total score | 14.4 ± 3.8 | 13.7 ± 3.7 | 17.0 ± 3.6 |
ADAS-Cog scorea | 48.0 ± 9.8 | 49.9 ± 8.9 | 40.3 ± 10.7 |
CDS-SOB scorea | 1.4 ± 0.56 | 1.4 ± 0.55 | 1.1 ± 0.63 |
NPI scorea | 8.4 ± 8.1 | 8.7 ± 8.6 | 7.0 ± 6.4 |
ADCS-ADL scorea | 55.9 ± 12.9 | 53.7 ± 13.1 | 64.5 ± 8.2 |
Composite SUVr | 1.40 (0.11) | 1.41 (0.09) | 1.37 (0.16) |
ApoE4 genotype | |||
Noncarriers | 7 (35.0) | 4 (25.0) | 3 (75.0) |
Heterozygotes | 7 (35.0) | 6 (37.5) | 1 (25.0) |
Homozygotes | 6 (30.0) | 6 (37.5) | 0 (0.0) |